N@N

Andrew Fein Reiterated (BIIB) at Strong Buy and Held Target at $325 on, Feb 16th, 2023

Andrew Fein of HC Wainwright & Co., Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $325 on, Feb 16th, 2023.

Andrew has made no other calls on BIIB in the last 4 months.

There are 9 other peers that have a rating on BIIB. Out of the 9 peers that are also analyzing BIIB, 4 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Steve Chesney of "Atlantic Equities" Maintained at Hold with Increased Target to $295 on, Thursday, December 1st, 2022
• Carter Gould of "Barclays" Maintained at Hold with Increased Target to $313 on, Wednesday, November 30th, 2022
• Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $247 on, Wednesday, November 30th, 2022
• Yatin Suneja of "Guggenheim" Maintained at Hold with Increased Target to $270 on, Friday, November 11th, 2022

These are the ratings of the 5 analyists that currently disagree with Andrew

---

• Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, November 30th, 2022
• Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $350 on, Tuesday, November 15th, 2022
• Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $325 on, Tuesday, November 1st, 2022
• Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $370 on, Wednesday, October 26th, 2022
• Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $310 on, Wednesday, October 26th, 2022

Contributing Sources

---